CN112543806B - 合成嵌合痘苗病毒 - Google Patents

合成嵌合痘苗病毒 Download PDF

Info

Publication number
CN112543806B
CN112543806B CN201980029677.9A CN201980029677A CN112543806B CN 112543806 B CN112543806 B CN 112543806B CN 201980029677 A CN201980029677 A CN 201980029677A CN 112543806 B CN112543806 B CN 112543806B
Authority
CN
China
Prior art keywords
scvacv
virus
clone
lister
vacv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201980029677.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN112543806A (zh
Inventor
戴维·埃文斯
瑞安·诺伊斯
塞思·莱德曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tonix Pharmaceuticals Inc
Original Assignee
Tonix Pharma Holdings Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tonix Pharma Holdings Ltd filed Critical Tonix Pharma Holdings Ltd
Priority to CN202510639606.8A priority Critical patent/CN121320271A/zh
Publication of CN112543806A publication Critical patent/CN112543806A/zh
Application granted granted Critical
Publication of CN112543806B publication Critical patent/CN112543806B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • A61K39/285—Vaccinia virus or variola virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/91—Cell lines ; Processes using cell lines

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN201980029677.9A 2018-05-02 2019-05-02 合成嵌合痘苗病毒 Active CN112543806B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202510639606.8A CN121320271A (zh) 2018-05-02 2019-05-02 合成嵌合痘苗病毒

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862665973P 2018-05-02 2018-05-02
US62/665,973 2018-05-02
PCT/US2019/030486 WO2019213452A1 (en) 2018-05-02 2019-05-02 Synthetic chimeric vaccinia virus

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202510639606.8A Division CN121320271A (zh) 2018-05-02 2019-05-02 合成嵌合痘苗病毒

Publications (2)

Publication Number Publication Date
CN112543806A CN112543806A (zh) 2021-03-23
CN112543806B true CN112543806B (zh) 2025-06-06

Family

ID=68386164

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201980029677.9A Active CN112543806B (zh) 2018-05-02 2019-05-02 合成嵌合痘苗病毒
CN202510639606.8A Pending CN121320271A (zh) 2018-05-02 2019-05-02 合成嵌合痘苗病毒

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202510639606.8A Pending CN121320271A (zh) 2018-05-02 2019-05-02 合成嵌合痘苗病毒

Country Status (13)

Country Link
US (1) US12529036B2 (cg-RX-API-DMAC7.html)
EP (1) EP3788142A4 (cg-RX-API-DMAC7.html)
JP (3) JP2021522784A (cg-RX-API-DMAC7.html)
CN (2) CN112543806B (cg-RX-API-DMAC7.html)
AR (1) AR115069A1 (cg-RX-API-DMAC7.html)
AU (1) AU2019262149B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020022181A2 (cg-RX-API-DMAC7.html)
CA (1) CA3099330A1 (cg-RX-API-DMAC7.html)
IL (1) IL278419B1 (cg-RX-API-DMAC7.html)
MX (1) MX2020011586A (cg-RX-API-DMAC7.html)
SG (1) SG11202010272PA (cg-RX-API-DMAC7.html)
TW (1) TW201946651A (cg-RX-API-DMAC7.html)
WO (1) WO2019213452A1 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL319942A (en) 2016-11-02 2025-05-01 Evans David Synthetic chimeric poxviruses, methods for their production, compositions containing them and uses thereof
WO2019089755A1 (en) 2017-10-31 2019-05-09 Western Oncolytics Ltd. Platform oncolytic vector for systemic delivery
CA3099330A1 (en) 2018-05-02 2019-11-07 Tonix Pharma Holdings Limited Synthetic chimeric vaccinia virus
CN115397998A (zh) * 2020-02-03 2022-11-25 希望之城 由天然或合成dna产生的基于痘病毒的载体及其用途
BR112022016992A2 (pt) * 2020-02-26 2022-10-25 Tonix Pharma Ltd Vacina com base em poxvírus recombinante contra ví-rus sars-cov-2
EP4153228A4 (en) 2020-05-17 2024-07-10 City of Hope CORONAVIRUS VACCINES BASED ON SYNTHETIC MODIFIED ANKARA VACCINE (SMVA) VIRUS
JP2023552289A (ja) 2020-11-19 2023-12-15 カリヴィル イムノセラピューティクス, インコーポレイテッド 腫瘍微小環境リモデリングによる腫瘍溶解性免疫療法
BR112023015467A2 (pt) 2021-02-02 2023-10-10 Geovax Inc Vetor viral de vaccinia ankara recombinante modificado, métodos para aumentar uma resposta imunológica a um antígeno alvo em um paciente e para prevenir, tratar ou induzir uma resposta imunológica contra um antígeno alvo, e, composição farmacêutica
EP4329786A4 (en) 2021-04-30 2024-12-11 KaliVir Immunotherapeutics, Inc. Oncolytic viruses for modified mhc expression
WO2023168286A1 (en) 2022-03-01 2023-09-07 Tonix Pharmaceuticals Holding Corp. Recombinant poxvirus based vaccine against the omicron strain of sars-cov-2 virus and variants thereof
CN116042656A (zh) * 2022-11-25 2023-05-02 中山大学附属第七医院(深圳) 一种猴痘病毒mRNA疫苗及其制备方法与用途
CN121992151A (zh) * 2026-02-03 2026-05-08 中国质量检验检测科学研究院 一种检测ⅰ、ⅱ型猴痘病毒分型的组合物及其分型检测试剂盒和应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110431228B (zh) * 2016-11-02 2024-04-02 戴维·埃文斯 合成嵌合痘病毒

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2787577A (en) 1953-12-01 1957-04-02 Lilly Co Eli Stable smallpox vaccine
US4754065A (en) 1984-12-18 1988-06-28 Cetus Corporation Precursor to nucleic acid probe
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
US6004777A (en) 1997-03-12 1999-12-21 Virogenetics Corporation Vectors having enhanced expression, and methods of making and uses thereof
US6723325B1 (en) 2001-04-23 2004-04-20 Acambis, Inc. Smallpox vaccine
CA2431349A1 (en) * 2002-06-06 2003-12-06 Xiao-Dan Yao Method of producing a recombinant virus
EP1668112A4 (en) 2003-06-20 2009-04-29 Protein Sciences Corp SARS IMMUNOGENOUS EXPRESSING VECTORS, SUCH VECTORS OR EXPRESSION PRODUCTS COMPRISING THOSE COMPOSITIONS, PROCESSES AND TESTS FOR THE PREPARATION AND USE THEREOF
EP1678292A4 (en) 2003-09-18 2008-05-07 Univ Emory IMPROVED MVA VACCINES
WO2005103259A1 (en) 2004-04-26 2005-11-03 University Health Network Sars-cov nucleocapsid protein epitopes and uses thereof
WO2006022215A1 (ja) 2004-08-23 2006-03-02 The Japan Health Sciences Foundation SARS-コロナウイルスタンパク質をコードするDNAを保有する組換えワクチニアウイルスDIs株、およびその利用
CN101020055B (zh) 2006-02-16 2012-08-08 中国疾病预防控制中心性病艾滋病预防控制中心 基于复制型痘苗病毒载体的sars疫苗
EP2415783B1 (en) 2006-10-16 2016-12-14 Genelux Corporation Modified vaccinia virus strains for use in a diagnostic and therapeutic method
WO2009117030A2 (en) 2007-12-19 2009-09-24 Macrogenics, Inc. Improved compositions for the prevention and treatment of smallpox
EP2697368B1 (en) * 2011-04-15 2019-06-05 Genelux Corporation Clonal strains of attenuated vaccinia viruses and methods of use thereof
FI20115914L (fi) 2011-09-16 2013-03-17 Oncos Therapeutics Ltd Muunnettu onkolyyttinen virus
WO2014160475A1 (en) 2013-03-13 2014-10-02 Aboody Karen S Tropic cell based virotherapy for the treatment of cancer
CA2909225C (en) * 2013-04-10 2019-06-18 Tot Shanghai R&D Center Co., Ltd. Mutant vaccinia virus strains, uses thereof and method of producing the same
EP3045181B1 (en) 2015-01-19 2018-11-14 Ludwig-Maximilians-Universität München A novel vaccine against the middle east respiratory syndrome coronavirus (MERS-CoV)
HK1248588A1 (zh) 2015-08-11 2018-10-19 Calidi Biotherapeutics, Inc. 用於癌症治疗中的天花疫苗
US11311615B2 (en) 2015-09-16 2022-04-26 Shin Nippon Biomedical Laboratories, Ltd. Vaccine compositions
JP2019528753A (ja) 2016-09-21 2019-10-17 スティーブン エイチ. ソーン, 高移動度グループboxi突然変異体
ES2702618B2 (es) 2017-09-04 2019-10-31 Inst De Salud Carlos Iii Producto de combinación que comprende una célula madre mesenquimatosa modificada y una sustancia antigénica.
CA3099330A1 (en) 2018-05-02 2019-11-07 Tonix Pharma Holdings Limited Synthetic chimeric vaccinia virus
US20210236619A1 (en) * 2018-05-02 2021-08-05 Tonix Pharma Holdings Limited Stem cells comprising synthetic chimeric vaccinia virus and methods of using them

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110431228B (zh) * 2016-11-02 2024-04-02 戴维·埃文斯 合成嵌合痘病毒

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Construction of an infectious horsepox virus vaccine from chemically synthesized DNA fragments;Ryan S Noyce et al;PLoS One;第13卷(第01期);摘要,第4、7页,表1 *

Also Published As

Publication number Publication date
CA3099330A1 (en) 2019-11-07
AR115069A1 (es) 2020-11-25
WO2019213452A1 (en) 2019-11-07
JP2021522784A (ja) 2021-09-02
EP3788142A1 (en) 2021-03-10
CN112543806A (zh) 2021-03-23
IL278419B1 (en) 2026-07-01
CN121320271A (zh) 2026-01-13
MX2020011586A (es) 2020-12-07
US20210230560A1 (en) 2021-07-29
IL278419A (cg-RX-API-DMAC7.html) 2020-12-31
JP2025178289A (ja) 2025-12-05
SG11202010272PA (en) 2020-11-27
US12529036B2 (en) 2026-01-20
WO2019213452A9 (en) 2021-01-14
TW201946651A (zh) 2019-12-16
JP2024051112A (ja) 2024-04-10
AU2019262149A1 (en) 2020-11-12
AU2019262149B2 (en) 2025-09-11
EP3788142A4 (en) 2022-04-27
BR112020022181A2 (pt) 2021-02-09

Similar Documents

Publication Publication Date Title
AU2019262149B2 (en) Synthetic chimeric vaccinia virus
TWI902763B (zh) 基於重組痘病毒之抗SARS-CoV-2病毒疫苗
CN109477089B (zh) 新型基因重组牛痘病毒
AU2017353868C1 (en) Synthetic chimeric poxviruses
KR102557818B1 (ko) 키메라 폭스바이러스 조성물 및 이의 용도
CN113215109B (zh) 非洲猪瘟多基因联合缺失减毒株的构建及作为疫苗的应用
KR20210132002A (ko) 변형된 오르토폭스 바이러스 벡터
CN112899290B (zh) 一种天然免疫抑制基因缺失的减毒非洲猪瘟病毒株及应用
JP2026041921A (ja) 合成改変ワクシニアアンカラ(sMVA)ベースのコロナウイルスワクチン
JP2003534780A (ja) 転移に関連する疾患の診断
CN113025629A (zh) 一种基因缺失的减毒非洲猪瘟病毒株及应用
CN113151310B (zh) 非洲猪瘟基因缺失弱毒株的构建及其作为疫苗的应用
CN114555793A (zh) 基于基因i177l缺失的新型非洲猪瘟减毒活疫苗的开发
KR20220148823A (ko) 천연 또는 합성 dna에 의해 생산된 폭스바이러스-기반 벡터 및 그의 용도
KR101234062B1 (ko) 림프구 내 유전자 도입용 재조합 바이러스 벡터
CN111107872A (zh) 有用于癌症免疫疗法的牛痘病毒突变体
CN116670153A (zh) 允许在稳定细胞系中高效生长的非洲猪瘟疫苗的基因组缺失
CN112261951A (zh) 包含合成嵌合痘苗病毒的干细胞及其使用方法
CN110546252A (zh) 具有广泛基因组对称的mva相关的新型痘苗病毒载体
KR20220082033A (ko) 레트로바이러스의 계내 생성을 위한 생산자 바이러스
HK40047064A (en) Synthetic chimeric vaccinia virus
HK40095569A (en) Recombinant poxvirus based vaccine against sars-cov-2 virus
HK40042130A (en) Stem cells comprising synthetic chimeric vaccinia virus and methods of using them
HK40078138A (en) Poxvirus-based vectors produced by natural or synthetic dna and uses thereof
HK40100707A (en) Genomic deletion in african swine fever vaccine allowing efficient growth in stable cell lines

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40047064

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
TG01 Patent term adjustment

Free format text: NEW EXPIRY DATE: 20390806

TG01 Patent term adjustment
TR01 Transfer of patent right

Effective date of registration: 20251120

Address after: CANACONA GA IN

Patentee after: THE GOVERNORS OF THE University OF ALBERTA

Country or region after: Canada

Patentee after: TONIX PHARMA HOLDINGS LTD.

Country or region after: Ireland

Address before: Tower of AI

Patentee before: EVANS DAVID

Country or region before: Canada

Patentee before: Ryan Noyce

Patentee before: TONIX PHARMA HOLDINGS LTD.

Country or region before: Ireland

TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20251208

Address after: Ireland

Patentee after: TONIX PHARMACEUTICALS Inc.

Country or region after: Ireland

Patentee after: TONIX PHARMA HOLDINGS LTD.

Address before: CANACONA GA IN

Patentee before: THE GOVERNORS OF THE University OF ALBERTA

Country or region before: Canada

Patentee before: TONIX PHARMA HOLDINGS LTD.

Country or region before: Ireland

TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20251217

Address after: Ireland

Patentee after: TONIX PHARMACEUTICALS Inc.

Country or region after: Ireland

Address before: Ireland

Patentee before: TONIX PHARMACEUTICALS Inc.

Country or region before: Ireland

Patentee before: TONIX PHARMA HOLDINGS LTD.

TR01 Transfer of patent right